The Losartan recall continues to expand after the Food and Drug Administration (FDA) announced the recall of additional lots of the blood pressure medication due to fears of carcinogen contamination. The latest Losartan recall includes five lots manufactured by Torrent Pharmaceutical after the medication was found to contain unsafe levels of N-methylnitrosobutyric acid, or NMBA.
Why is NMBA Dangerous?
NMBA is a known animal carcinogen and believed to be a potential human carcinogen. Like NDEA and NDMA, the compounds found in previous Losartan and Valsartan recalls, long term exposure to NMBA at unsafe levels could lead to development of certain types of cancers, including:
- Liver Cancer
- Stomach Cancer
- Colon Cancer
- Intestinal Cancer
- Prostate Cancer
- Lower Esophageal Cancer
- Non-Hodgkin’s Lymphoma
- Multiple Myeloma
- Pancreatic Cancer
When Was this Losartan Recall Announced?
The FDA announced the latest Torrent Losartan recall on September 19, 2019, and the company issued a formal announcement of the recall on September 23. This latest recall marks the sixth time that Torrent has recalled lots of its Losartan products due to potential carcinogen contamination since the recalls began in 2018.
Which Lots of Losartan Were Recalled?
The lots included in this latest Losartan recall are listed below:
Product Name, Strength, and Package Count
Losartan Potassium Tablets, USP 50mg, 1000 count
Losartan Potassium Tablets, USP 100mg, 90 count
Losartan Potassium Tablets, USP 100mg, 1000 count
Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count
Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count.
GoldenbergLaw Can Help
GoldenbergLaw is currently investigating cases where an individual has taken Losartan for at least a year, received a Losartan recall letter, and has been diagnosed with prostate cancer (before age 60), lower esophageal cancer, non-hodgkins lymphoma, leukemia, multiple myeloma, colon, stomach, intestinal, or pancreatic cancer. If you or a loved one has taken Losartan and been diagnosed with one of these cancers, please contact us today for a free consultation. We have over 30 years of experience holding drug manufacturers accountable for negligence, let us deliver the Gold Standard advocacy you deserve.